Literature DB >> 20101093

TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice.

Yu Wang1, Hafid Ait-Oufella, Olivier Herbin, Philippe Bonnin, Bhama Ramkhelawon, Soraya Taleb, Jin Huang, Georges Offenstadt, Christophe Combadière, Laurent Rénia, Jason L Johnson, Pierre-Louis Tharaux, Alain Tedgui, Ziad Mallat.   

Abstract

Complicated abdominal aortic aneurysm (AAA) is a major cause of mortality in elderly men. Ang II-dependent TGF-beta activity promotes aortic aneurysm progression in experimental Marfan syndrome. However, the role of TGF-beta in experimental models of AAA has not been comprehensively assessed. Here, we show that systemic neutralization of TGF-beta activity breaks the resistance of normocholesterolemic C57BL/6 mice to Ang II-induced AAA formation and markedly increases their susceptibility to the disease. These aneurysms displayed a large spectrum of complications on echography, including fissuration, double channel formation, and rupture, leading to death from aneurysm complications. The disease was refractory to inhibition of IFN-gamma, IL-4, IL-6, or TNF-alpha signaling. Genetic deletion of T and B cells or inhibition of the CX3CR1 pathway resulted in partial protection. Interestingly, neutralization of TGF-beta activity enhanced monocyte invasiveness, and monocyte depletion markedly inhibited aneurysm progression and complications. Finally, TGF-beta neutralization increased MMP-12 activity, and MMP-12 deficiency prevented aneurysm rupture. These results clearly identify a critical role for TGF-beta in the taming of the innate immune response and the preservation of vessel integrity in C57BL/6 mice, which contrasts with its reported pathogenic role in Marfan syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101093      PMCID: PMC2810071          DOI: 10.1172/JCI38136

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  59 in total

1.  Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis.

Authors:  A Daugherty; M W Manning; L A Cassis
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 2.  Abdominal aortic aneurysm: pathogenesis and implications for management.

Authors:  Jonathan Golledge; Juanita Muller; Alan Daugherty; Paul Norman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-09-14       Impact factor: 8.311

3.  Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages.

Authors:  M W Feinberg; M K Jain; F Werner; N E Sibinga; P Wiesel; H Wang; J N Topper; M A Perrella; M E Lee
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

4.  Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography.

Authors:  Chiara Barisione; Richard Charnigo; Deborah A Howatt; Jessica J Moorleghen; Debra L Rateri; Alan Daugherty
Journal:  J Vasc Surg       Date:  2006-08       Impact factor: 4.268

5.  TbetaR-I(6A) is a candidate tumor susceptibility allele.

Authors:  B Pasche; P Kolachana; K Nafa; J Satagopan; Y G Chen; R S Lo; D Brener; D Yang; L Kirstein; C Oddoux; H Ostrer; P Vineis; L Varesco; S Jhanwar; L Luzzatto; J Massagué; K Offit
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

6.  Aneurysm syndromes caused by mutations in the TGF-beta receptor.

Authors:  Bart L Loeys; Ulrike Schwarze; Tammy Holm; Bert L Callewaert; George H Thomas; Hariyadarshi Pannu; Julie F De Backer; Gretchen L Oswald; Sofie Symoens; Sylvie Manouvrier; Amy E Roberts; Francesca Faravelli; M Alba Greco; Reed E Pyeritz; Dianna M Milewicz; Paul J Coucke; Duke E Cameron; Alan C Braverman; Peter H Byers; Anne M De Paepe; Harry C Dietz
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

7.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms.

Authors:  R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

8.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice.

Authors:  A Daugherty; M W Manning; L A Cassis
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 9.  Transforming growth factor-betas and vascular disorders.

Authors:  Alex Bobik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-05-04       Impact factor: 8.311

10.  Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice.

Authors:  Z Mallat; A Gojova; C Marchiol-Fournigault; B Esposito; C Kamaté; R Merval; D Fradelizi; A Tedgui
Journal:  Circ Res       Date:  2001-11-09       Impact factor: 17.367

View more
  168 in total

1.  Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Venkateswaran Subramanian; Haruhito A Uchida; Talha Ijaz; Jessica J Moorleghen; Deborah A Howatt; Anju Balakrishnan
Journal:  J Cardiovasc Pharmacol       Date:  2012-01       Impact factor: 3.105

Review 2.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

3.  Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease.

Authors:  Wanli Ma; Weihong Han; Peter A Greer; Rubin M Tuder; Haroldo A Toque; Kevin K W Wang; R William Caldwell; Yunchao Su
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

4.  Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase.

Authors:  Takehiko Takayanagi; Kevin J Crawford; Tomonori Kobayashi; Takashi Obama; Toshiyuki Tsuji; Katherine J Elliott; Tomoki Hashimoto; Victor Rizzo; Satoru Eguchi
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

5.  TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms.

Authors:  Stoyan N Angelov; Jie Hong Hu; Hao Wei; Nathan Airhart; Minghui Shi; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-20       Impact factor: 8.311

6.  The endothelium: paracrine mediator of aortic dissection.

Authors:  Francesca Seta; Richard A Cohen
Journal:  Circulation       Date:  2014-05-07       Impact factor: 29.690

7.  Castration of male mice prevents the progression of established angiotensin II-induced abdominal aortic aneurysms.

Authors:  Xuan Zhang; Sean Thatcher; Congqing Wu; Alan Daugherty; Lisa A Cassis
Journal:  J Vasc Surg       Date:  2014-01-16       Impact factor: 4.268

8.  Rapamycin Treatment Attenuates Angiotensin II -induced Abdominal Aortic Aneurysm Formation via VSMC Phenotypic Modulation and Down-regulation of ERK1/2 Activity.

Authors:  Fei-Fei Li; Xiao-Ke Shang; Xin-Ling Du; Shu Chen
Journal:  Curr Med Sci       Date:  2018-03-15

9.  GM-CSF contributes to aortic aneurysms resulting from SMAD3 deficiency.

Authors:  Ping Ye; Wenhao Chen; Jie Wu; Xiaofan Huang; Jun Li; Sihua Wang; Zheng Liu; Guohua Wang; Xiao Yang; Peng Zhang; Qiulun Lv; Jiahong Xia
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

10.  Roles of Nicotine in the Development of Intracranial Aneurysm Rupture.

Authors:  Yoshinobu Kamio; Takeshi Miyamoto; Tetsuro Kimura; Kazuha Mitsui; Hajime Furukawa; Dingding Zhang; Kimihiko Yokosuka; Masaaki Korai; Daisuke Kudo; Ronald J Lukas; Michael T Lawton; Tomoki Hashimoto
Journal:  Stroke       Date:  2018-10       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.